STAR — Strides Pharma Science Income Statement
0.000.00%
- IN₹82.50bn
- IN₹97.11bn
- IN₹45.65bn
- 83
- 32
- 98
- 85
Annual income statement for Strides Pharma Science, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | R2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 33,159 | 30,703 | 36,884 | 38,901 | 45,653 |
| Cost of Revenue | |||||
| Gross Profit | 17,972 | 13,672 | 18,567 | 19,314 | 23,733 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 28,766 | 36,071 | 35,615 | 37,086 | 39,901 |
| Operating Profit | 4,393 | -5,368 | 1,269 | 1,815 | 5,752 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 2,754 | -6,525 | -2,862 | -1,148 | 4,869 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2,438 | -4,743 | -2,309 | -1,439 | 4,094 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 2,684 | -4,602 | -2,026 | -706 | 35,935 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2,684 | -4,602 | -2,026 | -706 | 35,935 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 27 | -30.4 | -23.6 | 0.192 | 47.1 |
| Dividends per Share |